Analysis of the impact of immunotherapy efficacy and safety in patients with gastric cancer and liver metastasis

Table 1 Comparison of clinical features of gastric cancer patients, n (%)

Clinical features	Hepatic metastases (n = 20)	No hepatic metastases (n = 28)	χ2	P value
Age in yr
< 65	4 (20.0)	11 (39.3)	2.020	0.212
≥ 65	16 (80.0)	17 (60.7)
Gender
Male	13 (65.0)	18 (64.3)	0.003	0.999
Female	7 (35.0)	10 (35.7)
ECOG score
0	6 (30.0)	5 (17.8)	9.116	0.011
1	8 (40.0)	22 (78.6)
2	6 (30.0)	1 (3.6)
Histological type
Adenocarcinoma	19 (95.0)	27 (96.4)	2.117	0.347
Signet-ring cell carcinoma	0 (0.0)	1 (3.6)
Unknown	1 (5.0)	0 (0.0)
PD-L1 expression
≥ 1%	9 (45.0)	11 (39.3)	0.206	0.902
< 1%	10 (50.0)	15 (53.6)
Unknown	1 (5.0)	2 (7.1)
Number of treatment lines
1	11 (55.0)	14 (50.0)	2.672	0.263
2	8 (40.0)	8 (28.6)
≥ 3	1 (5.0)	6 (21.4)
Treatment plan
Chemotherapy + immunotherapy	19 (95.0)	26 (92.8)	0.777	0.658
Antiangiogenic therapy + immunotherapy	1 (5.0)	1 (3.6)
Immunotherapy	0 (0.0)	1 (3.6)

PD-L1: Programmed cell death ligand 1.